Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1600 1641 1642 1644 1671 1681
This examiner grants 80% of resolved cases
Lindsay Michelle Dunn has resolved 5 cases in Art Unit 1600, with an allowance rate of 80.0%. The interview lift is 0.0%, and the median days to allowance is 1216. While the allowance rate is high, the small sample size of 5 cases should be taken into account when planning a prosecution strategy in Tech Center 1600.
The 80.0% allowance rate suggests a favorable outlook, but the 0.0% interview lift indicates that interviews have not impacted the outcome of these cases. The median days to allowance of 1216 reflects a typical timeline for applications in this field. Practitioners should note that the high success rate is based on a very limited number of resolved cases.
With a median pendency of 1216 days and no lift from interviews, the current data suggests that written prosecution is sufficient to achieve the baseline allowance rate. However, as the examiner handles more than 5 cases, these trends may evolve.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18053904 | STABLE FORMULATIONS COMPRISING A BISPECIFIC BCMA/CD3 ANTIBODY | Non-Final OA | JANSSEN BIOTECH, INC. |
| 18365950 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR GPRC5D AND BCMA | Non-Final OA | Juno Therapeutics, Inc. |
| 18285205 | CITRULLINATED PROTEINS AS BIOMARKERS AND THERAPY TARGETS FOR CANCER | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18034621 | CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL EXPRESSING CXCL12 RECEPTOR | Final Rejection | RIKEN |
| 18287551 | CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS | Non-Final OA | Imperial College Innovations Limited |
| 18554263 | DPEP-1 BINDING AGENTS AND METHODS OF USE | Non-Final OA | National Research Council of Canada |
| 18107573 | MAGE-A1 SPECIFIC T CELL RECEPTOR AND USES THEREOF | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 18483485 | TREATMENT OF DIABETES BY ENHANCEMENT OF PANCREATIC ISLET ENGRAFTMENT THROUGH REGENERATIVE IMMUNE MODULATION | Non-Final OA | CREATIVE MEDICAL TECHNOLOGIES, INC. |
| 18394422 | METHOD OF TREATING A PATIENT DIAGNOSED WITH AN INTERSTITIAL LUNG DISEASE | Non-Final OA | Vicore Pharma AB |
| 18554248 | NOVEL DARPIN BASED CD70 ENGAGERS | Non-Final OA | MOLECULAR PARTNERS AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy